Clinical trial
Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer
NCT00345293 · Rockefeller University, Other · Completed
Key facts
| NCT number | NCT00345293 |
|---|---|
| Title | Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer |
| Official title | A Phase I/II Study of Autologous Dendritic Cells Pulsed With Apoptotic Tumor Cells (DC/PC3) Administered Subcutaneously to Prostate Cancer Patients. |
| Lead sponsor | Rockefeller University, Other |
| Collaborators | Memorial Sloan Kettering Cancer Center |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological |
| Interventions | autologous dendritic cell vaccine (DC/PC3) |
| Enrollment | 13 |
| Start date | Jun 1, 2006 |
| Primary completion | Dec 1, 2013 |
| Completion | Mar 1, 2015 |
| First posted | Jun 28, 2006 |
| Last update posted | Apr 18, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: